19 February 2019 – Guardian
Two UK directors of Vertex Pharmaceuticals, the company in a current standoff with the NHS over the high price of its breakthrough cystic fibrosis drug, made over £15m from share options in 2017.
Vertex refuses to drop the price of Orkambi, the drug that treats the underlying causes of the life-shortening disease, to a level the NHS can afford. The two-year negotiations have been in stalemate for six months, while children and young adults with cystic fibrosis who could be helped suffer infections and irretrievably lose some of their lung function.
Ed. WEALTH WARNING – Neither I nor Brunswicks’ are licenced to give financial advice and nothing in this issue, or any other issue of Brunswicks’ Healthcare Review’ should be construed as advice, financial or otherwise, to anyone. Remember that the price of shares can fall as well as increase.